Brief: BioXcel Therapeutics Announces Positive FDA Pre-SNDA Meeting Comments For SNDA Submission For Bxcl501 In Agitation Associated With Bipolar Disorders Or Schizophrenia
18/08/2025 14:53
Aug 18 (Reuters) - BioXcel Therapeutics Inc BTAI.O: BIOXCEL THERAPEUTICS ANNOUNCES POSITIVE FDA PRE-SNDA MEETING COMMENTS FOR SNDA SUBMISSION FOR BXCL501 IN AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA Source text: ID:nGNX5BcLbh Further company coverage: BTAI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty